Enterprise Value
1.556B
Cash
1.261B
Avg Qtr Burn
-86.95M
Short % of Float
14.96%
Insider Ownership
2.47%
Institutional Own.
97.25%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Vepdegestrant (ARV-471) (oral ER-targeting PROTAC® protein degrader) + palbociclib Details Breast cancer, Cancer, Solid tumor/s | Phase 3 Data readout | |
Vepdegestrant (ARV-471)(oral ER-targeting PROTAC® protein degrader) Details Breast cancer, Cancer, Solid tumor/s | Phase 3 Data readout | |
Vepdegestrant (ARV-471) Details Cancer, Breast cancer, Solid tumor/s | Phase 2 Data readout | |
ARV-766 +/- abiraterone Details Castration-resistant prostate cancer, Solid tumor/s, Cancer, Prostate cancer | Phase 1/2 Data readout | |
Vepdegestrant (ARV-471)+CDK7 inhibitor (samuraciclib) Details Cancer, Solid tumor/s | Phase 1/2 Update | |
Vepdegestrant (ARV-471)+CDK4 inhibitor Details Solid tumor/s, Cancer | Phase 1/2 Update | |
Bavdegalutamide (ARV-110) (PROTAC protein degrader) +/- abiraterone Details Prostate cancer, Cancer, Castration-resistant prostate cancer, Solid tumor/s | Phase 1/2 Update | |
Vepdegestrant (ARV-471) Details Cancer, Breast cancer, Solid tumor/s | Phase 1 Data readout | |
ARV-102 (PROTAC® protein degrader) Details Neurodegenerative disease | Phase 1 Data readout |